Howard Colman

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint Molecular predictors in glioblastoma: toward personalized therapy
    Howard Colman
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston, TX 77030, USA
    Arch Neurol 65:877-83. 2008
  2. doi request reprint Brain tumor stem cells
    Erik Sulman
    Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Curr Probl Cancer 32:124-42. 2008
  3. ncbi request reprint Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710
    Howard Colman
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 66:818-24. 2006
  4. ncbi request reprint Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas
    Howard Colman
    Department of Neuro Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Am J Surg Pathol 30:657-64. 2006
  5. pmc Glioma-associated cancer-initiating cells induce immunosuppression
    Jun Wei
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 16:461-73. 2010
  6. doi request reprint Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma
    Tobias Walbert
    Department of Neuro Oncology, Unit 0431, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, P O Box 301402, Houston, TX, 77230 1402, USA
    J Neurooncol 102:273-80. 2011
  7. pmc Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma
    Krishna P L Bhat
    Department of Pathology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA Electronic address
    Cancer Cell 24:331-46. 2013
  8. ncbi request reprint Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma
    Christopher E Pelloski
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:2288-94. 2007
  9. pmc Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells
    Jun Fu
    Brain Tumor Center, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 73:3062-74. 2013
  10. pmc A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma
    Mark R Gilbert
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Unit 431, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 12:1167-72. 2010

Detail Information

Publications33

  1. doi request reprint Molecular predictors in glioblastoma: toward personalized therapy
    Howard Colman
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston, TX 77030, USA
    Arch Neurol 65:877-83. 2008
    ....
  2. doi request reprint Brain tumor stem cells
    Erik Sulman
    Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Curr Probl Cancer 32:124-42. 2008
  3. ncbi request reprint Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710
    Howard Colman
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 66:818-24. 2006
    ..The aim of this study was to determine whether recombinant human interferon beta-1a (rhIFN-beta), when given after radiation therapy, improves survival in glioblastoma...
  4. ncbi request reprint Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas
    Howard Colman
    Department of Neuro Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Am J Surg Pathol 30:657-64. 2006
    ..These results also suggest that pHH3 staining may be a useful method in other neoplasms in which accurate determination of proliferation potential is relevant to tumor grading or clinical treatment decision-making...
  5. pmc Glioma-associated cancer-initiating cells induce immunosuppression
    Jun Wei
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 16:461-73. 2010
    ....
  6. doi request reprint Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma
    Tobias Walbert
    Department of Neuro Oncology, Unit 0431, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, P O Box 301402, Houston, TX, 77230 1402, USA
    J Neurooncol 102:273-80. 2011
    ..The combination, however, is promising for patients with recurrent high-grade AG...
  7. pmc Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma
    Krishna P L Bhat
    Department of Pathology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA Electronic address
    Cancer Cell 24:331-46. 2013
    ..We further show that the MES signature, CD44 expression, and NF-κB activation correlate with poor radiation response and shorter survival in patients with GBM. ..
  8. ncbi request reprint Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma
    Christopher E Pelloski
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:2288-94. 2007
    ..We sought to evaluate the clinical significance of GBM subtypes as defined by EGFRvIII status...
  9. pmc Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells
    Jun Fu
    Brain Tumor Center, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 73:3062-74. 2013
    ..Our results suggest that GBM characterized by high-expressing Olig2 GIC may exhibit greater sensitivity to NVP-HSP990 treatment, establishing a foundation for further investigation of the role of HSP90 signaling in GBM...
  10. pmc A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma
    Mark R Gilbert
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Unit 431, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 12:1167-72. 2010
    ..Multiple cytostatic agents can be safely combined with dose-dense temozolomide. The factorial-based phase II portion of this study is currently ongoing...
  11. pmc MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma
    Andreana L Rivera
    Departments of Pathology and Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0097, Houston, TX 77030, USA
    Neuro Oncol 12:116-21. 2010
    ..Since this biomarker has also been shown to predict response to alkylating agents, perhaps MGMT promoter methylation represents a general, favorable prognostic factor in GBM...
  12. doi request reprint Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma
    Shlomit Yust-Katz
    Department of Neuro Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 119:2747-53. 2013
    ..Lonafarnib is an oral selective farnesyltransferase inhibitor, a class of drugs which have shown activity in preclinical glioma models. Temozolomide (TMZ) is an alkylating agent that is the first-line chemotherapy for glioblastoma...
  13. pmc A multigene predictor of outcome in glioblastoma
    Howard Colman
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77401, USA
    Neuro Oncol 12:49-57. 2010
    ..The profile has potential clinical application both for optimization of therapy in GBM and for the identification of novel therapies targeting tumors refractory to standard therapy...
  14. doi request reprint Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma
    Pierre Giglio
    Department of Neuro Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 118:3599-606. 2012
    ..Here, results of the AG arm of the study are reported, using this drug combination...
  15. doi request reprint Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway
    Ke Sai
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Neurooncol 107:487-501. 2012
    ..Taken together, our data indicate that WP1193 is a potent small molecule inhibitor of the JAK2/STAT3 pathway that shows promise as a therapeutic agent against GBM by targeting GSCs...
  16. doi request reprint Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma
    Morris D Groves
    Departments of Neuro Oncology, The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Neurooncol 94:229-34. 2009
    ..We chose to measure these molecules in the cerebrospinal fluid (CSF) of melanoma, breast, and lung cancer patients being evaluated for neoplastic meningitis (NM)...
  17. ncbi request reprint Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma
    Christopher E Pelloski
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 12:3935-41. 2006
    ..This study was conducted to determine whether any of these markers are associated with survival time and response to radiation in glioblastoma...
  18. pmc Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells
    Jeannine Garnett
    Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Neoplasia 15:73-84. 2013
    ..These results suggest that the c-Met/HGF signaling axis is enhanced by ΔEGFR through increased STAT3-dependent HGF expression and that targeting c-Met in Mes GBMs may be an important strategy for therapy...
  19. doi request reprint REST regulates oncogenic properties of glioblastoma stem cells
    Mohamed M Kamal
    Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Stem Cells 30:405-14. 2012
    ..Thus, based on our results, we propose that a novel function of REST is to maintain self-renewal and other oncogenic properties of GSCs and that REST can play a major role in mediating tumorigenicity in GBM...
  20. doi request reprint A High Notch Pathway Activation Predicts Response to γ Secretase Inhibitors in Proneural Subtype of Glioma Tumor-Initiating Cells
    Norihiko Saito
    Department of Neuro Oncology, Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Stem Cells 32:301-12. 2014
    ..Stem Cells 2014;32:301-312. ..
  21. pmc Tie2/TEK modulates the interaction of glioma and brain tumor stem cells with endothelial cells and promotes an invasive phenotype
    Dan Liu
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 1:700-9. 2010
    ....
  22. ncbi request reprint The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors
    J Matthew McDonald
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:1468-77. 2005
    ..The authors sought to determine whether histology was an equivalent or superior predictor of outcome compared with 1p/19q status in 131 patients with AO tumors...
  23. pmc The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma
    Krishna P L Bhat
    Department of Pathology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Genes Dev 25:2594-609. 2011
    ..Our studies uncover a direct role for TAZ and TEAD in driving the MES differentiation of malignant glioma...
  24. pmc A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies
    Morris D Groves
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 10:208-15. 2008
    ..IVent topotecan is well tolerated, but provides no added benefit over other IVent therapies. Because of its modest side effect profile, combining IVent topotecan with other IVent or systemic interventions should be considered...
  25. ncbi request reprint Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death
    Hong Jiang
    Brain Tumor Center, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Natl Cancer Inst 99:1410-4. 2007
    ..Our results show for the first time that brain tumor stem cells are susceptible to adenovirus-mediated cell death via autophagy in vitro and in vivo...
  26. pmc Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme
    Vinay K Puduvalli
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 10:216-22. 2008
    ..The results also provide support for similar strategies using combination therapies with newer targeted antiangiogenic agents to generate effective therapies against malignant gliomas...
  27. pmc Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway
    Jun Wei
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Mol Cancer Ther 9:67-78. 2010
    ..These findings indicate that cancer-initiating cells contribute to the immune evasion of GBM and that blockade of the STAT3 pathway has therapeutic potential...
  28. ncbi request reprint YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma
    Christopher E Pelloski
    Department of Radiation Oncology, Neuro Oncology, and Pathology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:3326-34. 2005
    ..Here we test these findings in a larger series of patients with glioblastoma, and in particular, determine if tumor YKL-40 expression is associated with radiation response...
  29. pmc FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis
    Nu Zhang
    Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 20:427-42. 2011
    ..FoxM1-β-catenin interaction controls Wnt target gene expression, is required for glioma formation, and represents a mechanism for canonical Wnt signaling during tumorigenesis...
  30. pmc Isolation and perivascular localization of mesenchymal stem cells from mouse brain
    Seok Gu Kang
    Department of Neurosurgery, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Neurosurgery 67:711-20. 2010
    ..Although originally isolated from the bone marrow, mesenchymal stem cells (MSCs) have recently been detected in other tissues. However, little is known about MSCs in the brain...
  31. pmc Exploratory analysis of the copy number alterations in glioblastoma multiforme
    Pablo Freire
    Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    PLoS ONE 3:e4076. 2008
    ..The wealth of existing mechanistic information about cancer cell biology provides a natural reference for the exploratory exercise...
  32. ncbi request reprint Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
    Heidi S Phillips
    Department of Tumor Biology and Angiogenesis, Genentech, Inc, South San Francisco, California 94080, USA
    Cancer Cell 9:157-73. 2006
    ..A robust two-gene prognostic model utilizing PTEN and DLL3 expression suggests that Akt and Notch signaling are hallmarks of poor prognosis versus better prognosis gliomas, respectively...
  33. ncbi request reprint Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma
    Janice M Nigro
    Department of Neurological Surgery Brain Tumor Research Center, University of California, School of Medicine, San Francisco, California, USA
    Cancer Res 65:1678-86. 2005
    ....